Anne McGeorge
CIK: 0001779934
Transaction Breakdown
High conviction signal
Position reduction
Derivative conversions
Compensation grants
Gifts, tax withholding, conversions, dispositions to the issuer and other codes
Discretionary Trading P&L
Holdings
Transaction History (13 total)
- Aug 10, 2026DNTH
Dianthus Therapeutics, Inc. /DE/
Sale(S)Direct1K shares at avg. $110.64$111K - Aug 10, 2026DNTH
Dianthus Therapeutics, Inc. /DE/
Sale(S)Direct1.8K shares at avg. $109.30$197K - Aug 10, 2026DNTH
Dianthus Therapeutics, Inc. /DE/
Sale(S)Direct700 shares at avg. $111.41$78K - Aug 10, 2026DNTH
Dianthus Therapeutics, Inc. /DE/
Exercise(M)Direct1.3K shares at avg. $19.36$24K - Aug 10, 2026DNTH
Dianthus Therapeutics, Inc. /DE/
Exercise(M)Direct6.5K shares at avg. $11.20$73K - Aug 10, 2026DNTH
Dianthus Therapeutics, Inc. /DE/
Sale(S)Direct1.5K shares at avg. $107.58$156K - Aug 10, 2026DNTH
Dianthus Therapeutics, Inc. /DE/
Sale(S)Direct2.8K shares at avg. $108.38$303K - Jul 27, 2026TOI
Oncology Institute, Inc.
Award(A)Direct41.2K shares- - May 21, 2026DNTH
Dianthus Therapeutics, Inc. /DE/
Award(A)DirectStock Option (Right to Buy)
6.1K shares- - Nov 20, 2025TOI
Oncology Institute, Inc.
Award(A)Direct67.9K shares- - Nov 20, 2025TOI
Oncology Institute, Inc.
Award(A)Direct40.1K shares- - May 22, 2025DNTH
Dianthus Therapeutics, Inc. /DE/
Award(A)DirectStock Option (Right to Buy)
12.5K shares- - Nov 22, 2024TOI
Oncology Institute, Inc.
Award(A)Direct56K shares-
| Type | Shares | Price | Ownership | |||
|---|---|---|---|---|---|---|
| Aug 10, 2026 |  DNTH Dianthus Therapeutics, Inc. /DE/ | Sale(S) | 1,000 | $110.64 | $110,640 | Direct |
| Aug 10, 2026 | DNTH Dianthus Therapeutics, Inc. /DE/ | Sale(S) | 1,800 | $109.30 | $196,740 | Direct |
| Aug 10, 2026 | DNTH Dianthus Therapeutics, Inc. /DE/ | Sale(S) | 700 | $111.41 | $77,987 | Direct |
| Aug 10, 2026 | DNTH Dianthus Therapeutics, Inc. /DE/ | Exercise(M) | 1,250 | $19.36 | $24,200 | Direct |
| Aug 10, 2026 | DNTH Dianthus Therapeutics, Inc. /DE/ | Exercise(M) | 6,500 | $11.20 | $72,800 | Direct |
| Aug 10, 2026 | DNTH Dianthus Therapeutics, Inc. /DE/ | Sale(S) | 1,450 | $107.58 | $155,991 | Direct |
| Aug 10, 2026 | DNTH Dianthus Therapeutics, Inc. /DE/ | Sale(S) | 2,800 | $108.38 | $303,464 | Direct |
| Jul 27, 2026 |  TOI Oncology Institute, Inc. | Award(A) | 41,165 | - | $0 | Direct |
| May 21, 2026 | DNTH Dianthus Therapeutics, Inc. /DE/ | Award(A) Stock Option (Right to Buy) | 6,090 | - | - | Direct |
| Nov 20, 2025 | TOI Oncology Institute, Inc. | Award(A) | 67,901 | - | - | Direct |
| Nov 20, 2025 | TOI Oncology Institute, Inc. | Award(A) | 40,123 | - | - | Direct |
| May 22, 2025 | DNTH Dianthus Therapeutics, Inc. /DE/ | Award(A) Stock Option (Right to Buy) | 12,500 | - | - | Direct |
| Nov 22, 2024 | TOI Oncology Institute, Inc. | Award(A) | 56,000 | - | $0 | Direct |
1-13 of 13 transactions
About McGeorge Anne
McGeorge Anne (SEC CIK 0001779934) files insider reports with the SEC as Director of Dianthus Therapeutics, Inc. /DE/ (DNTH) and Director of Oncology Institute, Inc. (TOI).
Signal8 holds 6 ownership filings by McGeorge Anne, all Form 4s, filed between Nov 25, 2024 and Aug 11, 2026. Those filings report 13 transactions, from Nov 22, 2024 to Aug 10, 2026. Signal8's Form 4 history starts in Sep 2024.
The business address on McGeorge Anne's filings is in NEW YORK, NY.
Recent filings by McGeorge Anne
- Aug 10, 2026: Open-market sales of DNTH shares (3 lines, Form 4, code S).
- Aug 10, 2026: Option exercises of DNTH shares (2 lines, Form 4, code M).
- Aug 10, 2026: Open-market sales of DNTH shares (2 lines, Form 4, code S).
- Jul 27, 2026: Grant or award of TOI shares (Form 4, code A).
- May 21, 2026: Grant or award of DNTH derivative securities (Form 4, code A).
Other insiders filing for Dianthus Therapeutics, Inc. /DE/ (DNTH)
- CARR EDWARD, CHIEF ACCOUNTING OFFICER
- Randhawa Simrat, EVP, Head of R&D
- Read Simon, Director
- Veness Adam M, SVP, General Counsel and Sec.
- Garcia Marino, CEO AND PRESIDENT
- Savitz Ryan, EVP, CFO & CBO